🇺🇸 FDA
Patent

US 9206159

Piperazine-piperidine compounds as hepatitis C virus inhibitors

granted A61KA61K31/496A61K31/506

Quick answer

US patent 9206159 (Piperazine-piperidine compounds as hepatitis C virus inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/496, A61K31/506, A61K31/55, A61K45/06